Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LGMN | Q99538 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739435 | 0.89 | HSD11B1 (0.42) | MAPTKDM4EOPRK1P2RY12HSD17B10 | |
| SCHEMBL3326910 | 0.85 | MAPT (0.44) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3327301 | 0.82 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4883732 | 0.80 | P2RY12 (0.53) | P2RY12 | |
| SCHEMBL4887321 | 0.80 | P2RY12 (0.58) | P2RY12 | |
| SCHEMBL4892954 | 0.75 | MAPT (0.39) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4786405 | 0.74 | P2RY12 (0.48) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3328130 | 0.73 | MEN1 (0.44) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4170972 | 0.73 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3328623 | 0.70 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008085119-A1 | NEW PYRIDINE ANALOGUES VIII 518 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | P2RY12, P2RY13, P2RY11 | MAPT 4725/4885ALDH1A1 2394/4885MEN1 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.